Trevi Therapeutics Provides Business Updates
- The Phase 2b CORAL trial in IPF patients with chronic cough has regulatory approval in 8 of the 10 expected countries. The trial includes a sample size re-estimation (SSRE) which is expected to occur in the second half of 2024 after approximately 50% of the patients in the trial are evaluable for the primary endpoint. Full enrollment in the trial is expected this year and topline results are expected in the first half of 2025, assuming no adjustments are made to the sample size as a result of the SSRE.
- The Phase 2a RIVER trial in RCC patients has been initiated and the first patient was randomized. Topline data from the trial is expected in the second half of 2024.
- The Human Abuse Potential study is active and dosing is expected to begin in January 2024, with topline data expected in the second half of 2024.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.